Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

NCT02399085 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: Tafasitamab
DRUG: Lenalidomide

Sponsor

MorphoSys AG